Literature DB >> 9442053

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.

M B Boffa1, W Wang, L Bajzar, M E Nesheim.   

Abstract

Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to pancreatic pro-carboxypeptidase B. Cleavage of the zymogen by thrombin/thrombomodulin generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely modulates fibrinolysis in vivo. In the present work we stably expressed recombinant TAFI in baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium, and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of activation by thrombin/thrombomodulin. Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with kcat = 0.55 s-1, K(m) = 0.54 microM, and Kd = 6.0 nM for rTAFI and kcat = 0.61 s-1, K(m) = 0.55 microM, and Kd = 6.6 nM for pTAFI. The respective TAFIa species also were prepared and compared with respect to thermal stability and enzymatic properties, including inhibition of fibrinolysis. The half-life of both enzymes at 37 degrees C is about 10 min, and the decay of enzymatic activity is associated with a quenching (to approximately 62% of the initial value at 60 min) of the intrinsic fluorescence of the enzyme. Stability was highly temperature-dependent, which, according to transition state theory, indicates both high enthalpy and entropy changes associated with inactivation (delta Ho++ approximately equal to 45 kcal/mol and delta So++ approximately equal to 80 cal/mol/K). Both species of TAFIa are stabilized by the competitive inhibitors 2-guanidinoethylmercaptosuccinic acid and epsilon-aminocaproic acid. rTAFIa and pTAFIa are very similar with respect to kinetics of cleavage of small substrates, susceptibility to inhibitors, and ability to retard both tPA-induced and plasmin-mediated fibrinolysis. These studies provide new insights into the thermal instability of TAFIa, a property which could be a significant regulator of its activity in vivo; in addition, they show that rTAFI and rTAFIa are excellent surrogates for the natural plasma-derived species, a necessary prerequisite for future studies of structure and function by site-specific mutagenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442053     DOI: 10.1074/jbc.273.4.2127

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

2.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

Review 3.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

4.  Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.

Authors:  Aruna Chhikara; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Pediatr       Date:  2016-08-03       Impact factor: 1.967

5.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

6.  Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Authors:  Jonathan H Foley; Paul F Cook; Michael E Nesheim
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

7.  The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Authors:  Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

8.  The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

Authors:  Kanchan Anand; Irantzu Pallares; Zuzana Valnickova; Trine Christensen; Josep Vendrell; K Ulrich Wendt; Herman A Schreuder; Jan J Enghild; Francesc X Avilés
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

9.  Functional differences between Streptococcus pyogenes cluster 1 and cluster 2b streptokinases are determined by their β-domains.

Authors:  Yueling Zhang; Zhong Liang; Kristofor Glinton; Victoria A Ploplis; Francis J Castellino
Journal:  FEBS Lett       Date:  2013-03-07       Impact factor: 4.124

Review 10.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.